We previously demonstrated that 24-h treatment with (Ϫ)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI) causes phosphorylation of G ␣11 protein at serine 154 and that this phosphorylation causes desensitization of serotonin (5-HT) 2A receptor signaling in A1A1v cells (Shi et al., 2007) . We now report that treatment of A1A1v cells with DOI for 24 h produces a greater reduction in the B max of To determine whether DOI increases phosphorylation of G ␣q/11 protein in vivo, rats were treated with 1 mg/kg/day DOI or saline for 1 to 7 days. Seven days of DOI treatment significantly decreased phospholipase C activity stimulated by an E max concentration of 5-HT by 40% and increased phosphorylation of G ␣q/11 proteins by 51% in the frontal cortex. These data suggest that DOI causes phosphorylation of G ␣q/11 in vivo and could thereby contribute to the desensitization of 5-HT 2A receptors.
To determine whether DOI increases phosphorylation of G ␣q/11 protein in vivo, rats were treated with 1 mg/kg/day DOI or saline for 1 to 7 days. Seven days of DOI treatment significantly decreased phospholipase C activity stimulated by an E max concentration of 5-HT by 40% and increased phosphorylation of G ␣q/11 proteins by 51% in the frontal cortex. These data suggest that DOI causes phosphorylation of G ␣q/11 in vivo and could thereby contribute to the desensitization of 5-HT 2A receptors.
Serotonin (5-HT) 2A receptors play important roles in the central nervous system (Roth et al., 1986; Hoyer et al., 1994) . Desensitization of 5-HT 2A/2C receptor signaling may underlie the mechanism of action of several drug treatments for neuropsychiatric disorders (Dean and Hayes, 1996) . For example, several antipsychotic drugs, such as olanzapine, desensitize both 5-HT 2A and 5-HT 2C receptors (Kuoppamä ki et al., 1995; Leysen et al., 1993; Roth and Ciaranello, 1991; Schmidt et al., 1995) . Mechanisms leading to and resulting from the desensitization of 5-HT 2A receptors may explain the 2-week delay in full symptomatic improvement seen with these antipsychotic drugs. However, the molecular mechanisms that underlie the desensitization of 5-HT 2A receptor signaling are not well understood.
Previous studies suggested that three possible mechanisms might be involved in the desensitization of 5-HT 2A receptors: receptor uncoupling from G proteins, internalization (sequestration of the receptor away from the cell surface) (Bhattacharyya et al., 2002; Hanley and Hensler, 2002) , or down-regulation (reduced ligand-bound receptor). For example, some in vivo and in vitro studies have demonstrated that agonist exposure resulted in the desensitization and downregulation 5-HT 2A receptors (Anji et al., 2000; Buckholtz et al., 1988; McKenna et al., 1989; Valdez et al., 2002) . However, other studies showed that agonists may cause desensitization without down-regulation or desensitization in the presence of increased densities of 5-HT 2A receptors (Akiyoshi et al., 1993; Grotewiel and Sanders-Bush, 1994; Roth et al., 1995) . The reduction of G-protein coupling to 5-HT 2A receptors has been suggested by a greater reduction in the B max of agonist DOI [(Ϫ)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl]-labeled high-affinity receptors than the reduction in B max of antagonist ketanserin-labeled 5-HT 2A receptors after chronic agonist treatment (McKenna et al., 1989) . These studies suggest that multiple mechanisms may be responsible for the desensitization of 5-HT 2A receptors, but with the specific mechanism(s) involved, dependent on the specific cellular milieu in which the receptors are expressed (Roth et al., 1998) . These findings further suggest that, although studies using cell culture models are informative, it is important to determine whether molecular mechanisms revealed in cell culture models reflect the nature of mammalian brain using complementary in vivo studies.
Our previous data in an embryonic rat cortical cell line, A1A1v cells, demonstrated that phosphorylation of G ␣11 protein on serine 154 by protein kinase C and calcium-calmodulin dependent kinase II contributes to agonist-induced desensitization of 5-HT 2A receptor signaling (Shi et al., 2007) . Exposure of A1A1v cells to DOI for 24 h increased phosphorylation of G ␣q/11 protein. Using site-directed mutagenesis, we found that mutation of serine 154 to alanine on G ␣11 protein reduced the desensitization of 5-HT 2A receptor signaling and prevented the increase in phosphorylation of G ␣q/11 protein caused by DOI. Mutation of G ␣11 protein serine 154 to aspartic acid, a phosphorylation mimic, directly reduced 5-HT 2A receptor signaling. In contrast, mutation of G ␣q to alanine had no effect on agonist-induced desensitization of 5-HT 2A receptor signaling.
As described above, it is important to determine whether the mechanisms revealed in cell culture models reflect the nature of the response in vivo; therefore, we examined the phosphorylation of G ␣q/11 protein in rat brain. Now we report the outcome of a time-course study to determine the impact of DOI on phosphorylation of G ␣q/11 protein and desensitization of 5-HT 2A receptor signaling in rat frontal cortex. In rat frontal cortex, G ␣11 protein mRNA is more abundant than G ␣q protein mRNA (Tanaka et al., 2000) , suggesting that increased phosphorylation of G ␣11 protein would affect 5-HT 2A receptor signaling in this brain region. Furthermore, we examined the effects of another drug that alters 5-HT 2A receptor signaling on phosphorylation of G ␣q/11 protein, a serotonin reuptake inhibitor, fluoxetine, which increases 5-HT 2A receptor signaling.
We further hypothesize that phosphorylation of G ␣11 protein reduces 5-HT 2A receptor signaling by altering the interactions of G ␣11 protein with other proteins such as the 5-HT 2A receptors. This hypothesis is consistent with our previous study, which measured phospholipase C (PLC) activity stimulated by a EC 80 dose of 5-HT or GTP␥S [guanosine 5Ј-3-O-(thio)triphosphate], and suggested that an alteration at the receptor or an alteration in coupling of 5-HT 2A receptors to G ␣q/11 protein occurs with agonist treatment (Damjanoska et al., 2004 Cell Culture and Transfections. A1A1v neuronal cells endogenously express the 5-HT 2A receptor signaling system and were kindly provided by Dr. William Clarke and Kelly Berg (University of Texas Health Science Center, San Antonio, TX). The A1A1v cells were grown in poly-L-ornithine-coated plates in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum in a humidified atmosphere containing 5% CO 2 . Serum was heat-inactivated and charcoal-treated to remove monoamines. Cells were treated with either 100 nM DOI or vehicle (Hanks' balanced buffer) for 24 h before harvesting for the receptor-binding assay. Cells were transiently transfected with either wild-type G ␣11 or mutant G ␣11 S154D using Lipofectamine Plus (Invitrogen) according to the manufacturer's recommendations. A total of 4 g/plate DNA was used in each transfection. After transfection (48 h), cells were harvested for radioligand binding assays.
Cell Homogenates. To harvest cells, culture plates were washed twice with ice-cold phosphate-buffered saline. We then added 50 mM Tris, pH 7.4, containing protease inhibitor cocktail (containing 104 M 4-(2-aminoethyl)benzenesulfonyl fluoride, 0.08 M aprotinin, 2 M leupeptin, 4 M bestatin, 1.5 M pepstatin A, and 1.4 M E-64, pH 7.4) from Sigma-Aldrich. Cells were harvested by scraping cells off of the surface of the plate. Cells were then centrifuged at 30,000g for 20 min at 4°C. The pellet was resuspended in 50 mM Tris buffer and stored at Ϫ80°C. The homogenates were thawed on the day of the binding assay and homogenized by hand with five up-and-down strokes with a glass/glass homogenizer and then centrifuged at 30,000g for 20 min. After centrifugation, the pellet was resuspended in 50 mM Tris buffer and incubated at 37°C for 15 min and centrifuged at 30,000g for 20 min. The resultant pellet was washed once and resuspended in binding assay buffer (50 mM Tris pH 7.4, 0.5 mM EDTA, and 10 mM MgSO 4 ). The final protein concentration was determined by using a bicinchoninic acid protein assay kit (Pierce Chemical, Rockford, IL). were incubated with the cell homogenates (ϳ100 g/tube protein) for 1.5 h at room temperature in the same assay buffer as described above. The concentration range of [ 125 I](Ϯ)-DOI was based on the K D in our previous study (Li et al., 1997 3 H]ketanserin concentrations (1.0 -30.0 nM) was incubated with cell homogenates containing ϳ100 g/tube protein for 1 h at room temperature in assay buffer. Prazosin (30 nM) was included in all assays to preclude binding to ␣ 1 receptors. Nonspecific binding was defined in the presence of 1 M spiperone. The reactions were terminated by filtration and washing as described above. The amount of [ 3 H]ketanserin on the filters was counted using a Beckman LS 6500 scintillation counter. All radioligand receptor binding assays were performed in triplicate in a final volume of 0.5 ml. Specific binding was defined as the total binding minus nonspecific binding. Determination of B max and K D values by either computer-assisted analyses of saturation data (Prism; GraphPad Software, Inc.) or by linear transformation of saturation data via Scatchard plots gave comparable results.
Animals. Male Sprague-Dawley rats (225-275 g; Harlan Laboratories, Indianapolis, IN) were housed two per cage in an environment controlled for temperature, humidity, and lighting (7:00 AM-7:00 PM). Food and water were provided ad libitum. Seven to 11 rats were used per experimental group. All procedures were conducted in accordance with the National Institutes of Health (Institute of Laboratory Animal Resources, 1996) as approved by the Loyola University Institutional Animal Care and Use Committee.
Animal Treatment Procedures. The rats were handled during the treatment periods to acclimate them to human contact and to minimize stress. Rats were randomly assigned to the various experimental groups, cage mates in the same experimental groups. The body weight of each rat was recorded every other day.
Sustained Agonist (DOI) Treatment. Rats received daily injections of DOI dissolved in 0.9% saline (1 mg/kg i.p.) for 1, 4, or 7 days or 0.9% saline (1 ml/kg i.p.) for 7 days. Rats receiving DOI injections for 1 or 4 days were given injections of 0.9% saline (1 ml/kg i.p.) on the days prior to the commencement of DOI treatment. Thus, every group received injections for a total of 7 days, which allowed us to control for any potential injection effects. Twenty-four hours after the last DOI treatment, the rats were decapitated. Brains were quickly removed, frozen on dry ice, and stored at Ϫ80°C for biochemical and molecular analyses.
Chronic Fluoxetine Treatment. Rats were injected with fluoxetine (10 mg/kg/day i.p.), dissolved in 0.9% saline or 0.9% saline (2 ml/kg i.p.) daily for 21 days. Eighteen hours after the last injection, the rats were decapitated. The brains were quickly removed, frozen on dry ice, and stored at Ϫ80°C. PLC Assay. 5-HT-and GTP␥S-stimulated PLC activity in frontal cortex was conducted as described previously (Damjanoska et al., 2003 (Damjanoska et al., , 2004 Wolf and Schutz, 1997) . In brief, membrane fractions were prepared from rat frontal cortex. Protein concentrations were determined using a bicinchoninic acid protein assay kit (Pierce Chemical). The membrane protein was diluted to a concentration of 30 g/100 l with a buffer containing 25 mM HEPES-Tris, 3 mM EGTA, 10 mM LiCl, 12 mM MgCl 2 , 1.44 mM sodium deoxycholate with 1 M GTP␥S (a nonhydrolyzable form of GTP), 300 nM free Ca 2ϩ , 1 mM unlabeled phosphatidylinositol, and 100 M [ 3 H]phosphatidylinositol (PerkinElmer Life and Analytical Sciences). Two concentrations of 5-HT were used to stimulate PLC activity: 0.3 M (EC 50 ) and 10.0 M (E max ) (Wolf and Schutz, 1997) . This extends our previous study, which used only a single EC 80 dose of 5-HT to measure the desensitization response to repeated DOI treatments (Damjanoska et al., 2004) . 5-HT-stimulated PLC activity in the frontal cortex is a selective measure of 5-HT 2A receptor function as previously demonstrated using selective antagonists (Wolf and Schutz, 1997) .
Analysis of Phosphorylation of G ␣q/11 Proteins. Frontal cortex tissues from rats treated with DOI and saline were homogenized in a 50 mM Tris buffer, pH 7.7, containing 150 mM NaCl, 10% sucrose, and 0.5 mM phenylmethanesulfonyl fluoride, 50 mM NaF, 2 mM activated sodium orthovanadate, and 1:1000 protease inhibitor cocktail (Sigma-Aldrich). The homogenate was then centrifuged for 60 min at 20,000g. The pellet was resuspended by sonication in a 20 mM Tris buffer, pH 8, containing 1 mM EDTA, 100 mM NaCl, and 1% sodium cholate. The resuspended pellet was agitated at 4°C for 60 min and was then centrifuged for 60 min at 100,000g. The supernatant was saved from each sample and stored at Ϫ80°C before use in the immunoprecipitation assay. Protein concentrations were measured using a bicinchoninic acid protein assay kit (Pierce Chemical).
Immunoprecipitation of G ␣q/11 proteins was performed as described previously (Shi et al., 2007 ) using a G ␣q/11 polyclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA). The immunoprecipitated G ␣q/11 proteins were resolved by loading 7 l of supernatant from each sample onto a SDS-polyacrylamide gel containing 0.1% SDS, 8% acrylamide/bisacrylamide (30:0.2), 4.6 M urea, and 375 mM Tris, pH 8.7. Gels loaded with samples from the DOI experiment were designed to contain three samples from the salinetreated control group and three samples from each DOI treatment group. Gels loaded with tissue from the fluoxetine experiment contained six samples from the 21-day fluoxetine treatment group and six samples of the 21-day saline treatment group. The proteins were electrophoretically transferred from the gels onto nitrocellulose or polyvinylidene difluoride membranes, and phosphorylated proteins were detected with a phospho-Ser/Thr/Tyr antibody (1:200; Spring Bioscience, Fremont, CA) as described previously (Shi et al., 2007) or with the Pro-Q Diamond Phosphoprotein Stain as per the manufacturer's directions (Invitrogen). Levels of G ␣q/11 proteins were examined to verify equal loading of protein in each lane (using G ␣q/11 antibody, 1:500; and a horseradish peroxidase-labeled, anti-rabbit antibody, 1:100,000; Santa Cruz Biotechnology Inc.).
Films were analyzed densitometrically using the Scion Image program (Scion Corp., Frederick, MD). For normalization, the integrated optical density (IOD) of phosphorylated G ␣q/11 protein bands on each blot were divided by the mean IOD of saline-treated animals and by the IOD of the respective G ␣q/11 protein bands (independent of their phosphorylation state).
A total of eight samples per group were analyzed for the DOI experiment. For each animal, immunoprecipitations were performed in triplicate, and the Western blot analysis of each immunoprecipitated sample was performed at least twice. The data presented for the DOI treatment are the means of all three immunoprecipitations. For the fluoxetine experiment, a total of six samples per group were analyzed. Immunoprecipitations for the fluoxetine treatment paradigm were performed twice, and the Western blot analysis of each immunoprecipitated sample was performed at least twice. The data are the means of six samples in one representative assay.
Statistical Analyses. All data are presented as group means Ϯ S.E.M. The K D and B max data were analyzed using Student t tests. The GTP␥S-sensitive binding data, 5-HT-stimulated PLC activity, and 5-HT to GTP␥S ratio data were analyzed using a two-way ANOVA followed by a Newman-Keuls post hoc analysis. GTP␥S-stimulated PLC activity was analyzed using one-way ANOVA. Because of nonhomogeneity of variance assessed using Bartlett's Chi Square (p Ͻ 0.05), data from the immunoprecipitation assays for the DOI-treatment paradigm were analyzed using nonparametric Kruskal-Wallis one-way ANOVA. This was followed by a NewmanKeuls post hoc analysis. The immunoprecipitation assays of the fluoxetine-treatment paradigm, comparing fluoxetine with saline treatment, were analyzed using a Student's t test. GB-STAT software (Dynamic Microsystems, Inc., Silver Spring, MD) was used for all statistical analyses. A probability level of p Ͻ 0.05 was considered to be statistically significant for all statistical tests. (Fig. 1) (Shi et al., 2007) However, in cells transfected with the phosphorylation state mimic G ␣11 S154D, GTP␥S-sensitive binding was reduced to 47.6 Ϯ 9.6% GTP␥S-sensitive binding in cells transfected with wild-type G ␣11 (Fig. 3) . These data suggest less 5-HT 2A -G protein coupling with the G ␣11 S154D phosphorylation mimic.
Results

Effect of DOI
Effect of in Vivo DOI Treatment on 5-HT-Stimulated PLC Activity. As shown in Fig. 4A , 5-HT stimulated PLC activity in the frontal cortex in a concentration-dependent manner. Pretreatment with daily injections of DOI (1 mg/kg) significantly decreased 10 M 5-HT-stimulated PLC activity in the frontal cortex of rats [F (2,42) ϭ 11.1, p ϭ 0.0001]. With the 10 M concentration, 5-HT-stimulated PLC activity was decreased by 32% after 4 days of DOI treatment (p Ͻ 0.01) and by 40% after 7 days (p Ͻ 0.01) of DOI treatment (Fig.  4A) . DOI treatment reduced the PLC response to 0.3 M 5-HT by 26% at 4 days and 39% at 7 days, but this difference did not reach statistical significance (Fig. 4A) Fig.  4B , DOI treatment for either 4 or 7 days did not significantly affect GTP␥S-stimulated PLC activity in the frontal cortex [F (2,21) ϭ 0.6, p ϭ 0.56]. Although the GTP␥S-stimulated PLC activity was not significantly altered, we examined the ratio of 5-HT-to GTP␥S-stimulated PLC activity to determine whether variations in the GTP␥S-stimulated PLC activity for individual animals would influence 5-HT-stimulated effects. As shown in Fig. 4C , DOI treatment decreased the ratio of 10 M 5-HT-to GTP␥S-stimulated PLC activity [F (2,41) ϭ 4.46, p ϭ 0.02] by 30% after 4 days (p Ͻ 0.05) and by 39% after 7 days (p Ͻ 0.05), similar to that seen by 10 M 5-HT stimulation directly (Fig. 4A) . With 0.3 M 5-HT stimulation, the DOI-induced reductions in the ratio on 5-HT to GTP␥S-stimulated PLC activity were not statistically significant (Fig.  4C) . 
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Effect of in Vivo DOI Treatment on Levels of Phosphorylated G ␣q/11 Proteins. Using immunoprecipitation and Western blots, we demonstrated that G ␣q/11 proteins in the frontal cortex are phosphorylated as shown in Fig. 5 . DOI treatment increased the levels of phosphorylated G ␣q/11 proteins in the frontal cortex in a time-dependent manner (Fig.  5, A and B) . The levels of phosphorylation of G ␣q/11 proteins were 2, 31, and 51% above control levels after 1, 4, and 7 days of sustained DOI treatment, respectively. A nonparametric Kruskal-Wallis one-way ANOVA revealed a significant (p Ͻ 0.05) overall effect of DOI treatment. Newman-Keuls post hoc analysis indicated that phosphorylation of G ␣q/11 proteins after 7 days of DOI treatment was significantly increased (p Ͻ 0.05) over saline controls and 1 day of DOI treatment ( Fig. 5A ). There was no significant effect of 4 days of DOI treatment on phosphorylation of G ␣q/11 proteins. The specificity of the immunoprecipitation of G ␣q/11 proteins is shown in Fig. 5C . A second method was used to detect the phosphorylated proteins on blots prepared with immunoprecipitated G ␣q/11 proteins. As shown in Fig. 5D , using the Pro-Q Diamond Phosphoprotein Stain, the levels of phosphorylated G ␣q/11 proteins were higher in frontal cortex from rats treated for 7 days with DOI compared with salinetreated controls.
Effect of in Vivo Chronic Fluoxetine Treatment on Phosphorylated Levels of G ␣q/11 Proteins. To determine whether the regulation of G protein phosphorylation is specific for agonist-induced desensitization or is a more general mechanism regulating 5-HT 2A receptor signaling, we examined G protein phosphorylation in a model of indirect and nonselective 5-HT receptor stimulation using treatment with the serotonin reuptake inhibitor fluoxetine. We examined G ␣q/11 protein phosphorylation in the frontal cortex of rats treated with chronic fluoxetine, based on our previous findings that 21 days of daily fluoxetine increases 5-HT 2A receptor-mediated PLC activity in rat frontal cortex (Damjanoska et al., 2003) . As shown in Fig. 6 , A and B, chronic fluoxetine treatment did not change the levels of phosphorylated G ␣q/11 proteins in the frontal cortex (Student's t test, p ϭ 0.89).
Discussion
In the present study, we found that 24-h DOI treatment causes down-regulation of 5-HT 2A receptors and uncoupling of G ␣11 protein from 5-HT 2A receptors in A1A1v cells. Our results also suggest that the increased phosphorylation of G ␣11 protein induced by DOI treatment results in an uncoupling of G proteins from 5-HT 2A receptors in A1A1v cells based on the use of a phosphorylation state mimic mutation, S154D, in G ␣11 protein. However, the phosphorylation state mimic did not reduce agonist binding to 5-HT 2A receptors. The additional effects of DOI treatment on receptor binding are consistent with our previous data suggesting that phosphorylation of G ␣11 protein contributes approximately half of the total desensitization response caused by DOI treatment (Shi et al., 2007) .
Previous studies found that chronic administration of the 5-HT 2A receptor agonist DOI resulted in reductions in the density of 5-HT 2A receptors in the cortex (Anji et al., 2000; Hensler and Truett, 1998; McKenna et al., 1989 ). In our current study, we found that DOI treatment significantly lowered the B max of 125 I](Ϯ)-DOI binding to 5-HT 2A receptors following 24-h DOI treatment in A1A1v cells and that the 46.5% reduction in agonist binding is much greater than the 24.8% reduction in antagonist binding. These relative differences in agonist and antagonist binding are consistent with previous studies on rat frontal cortex in which agonist binding was reduced 86% and antagonist binding was reduced 51% (McKenna et al., 1989 ). Based on the ter- Fig. 4 . Effect of sustained DOI treatment on 5-HT 2A receptor-mediated PLC activity in rat frontal cortex. A, sustained DOI treatment decreased PLC activity stimulated by an E max concentration of 5-HT (10 M) but had no significant effect at the EC 50 (0.3 M) concentration ‫ءء(‬ indicates p Ͻ 0.01 compared with the respective treatment group at the EC 50 concentration of 5-HT; tt indicates p Ͻ 0.01 compared with the saline treatment group using the same concentration of 5-HT). The data presented are the levels of DOI-stimulated PLC activity above the baseline stimulated by GTP␥S. B, sustained DOI treatment did not alter GTP␥S-stimulated PLC activity. C, sustained DOI treatment decreased the ratio of 5-HT-to GTP␥S-stimulated PLC activity at the E max concentration of 5-HT but not at the EC 50 concentration of 5-HT ‫ء(‬ indicates p Ͻ 0.05 compared with the respective treatment group at the EC 50 concentration of 5-HT; t indicates p Ͻ 0.05 compared with the saline treatment group at the same concentration of 5-HT). The data represent the mean Ϯ S.E.M. of eight rats per group. Fig. 5 . Effect of sustained DOI treatment (1 mg/kg i.p., 1, 4, and 7 days) on levels of phosphorylated G ␣q/11 . A, sustained DOI treatment significantly increased phosphorylation of G ␣q/11 proteins compared with saline treatment and DOI treatment for 1 day indicated by ‫ء‬ (p Ͻ 0.05) using one-way ANOVA and Newman-Keuls multiple range test. The data represent the mean Ϯ S.E.M. of eight rats per group. B, a representative blot of saline (Sal), DOI 1-day (D1), DOI 4-day (D4), and DOI 7-day (D7) treatments. The blot was probed with a phosphorylation-dependent antibody and then with an antibody for G ␣q/11 . C, to control for specificity of the immunoprecipitation of G ␣q/11 , a Western blot was prepared with 500 g of membrane protein immunoprecipitated with G ␣q/11 antibody (lane 1), no membrane protein (buffer only) immunoprecipitated with G ␣q/11 antibody (lane 2), 500 g of membrane protein immunoprecipitated with normal rabbit IgG (lane 3), 100 g of membrane protein immunoprecipitated with normal rabbit IgG (lane 4), and 10 g of membrane protein (lanes 5 and 6) probed with the G ␣q/11 antibody. D, to verify the changes in phosphorylation of G ␣q/11 proteins, the Pro-Q Diamond Phosphoprotein Stain (Pro-Q) was used on blots prepared with immunoprecipitated G ␣q/11 protein from the frontal cortex from rats treated with DOI (D7) or saline (Sal) for 7 days. The decreased coupling of 5-HT 2A receptors with G proteins may be due to the phosphorylation of 5-HT 2A receptors, phosphorylation of G proteins, or a reduction in G protein levels. Results from previous studies (Damjanoska et al., 2004; Roth et al., 1995) suggest that the agonist-induced desensitization of 5-HT 2A receptor signaling is not likely due to alterations in the levels of G proteins. Although phosphorylation of 5-HT 2A receptors could result in the uncoupling of 5-HT 2A receptors with G proteins and 5-HT 2A receptors containing several consensus sites for effector kinases, protein kinase C and calcium-calmodulin dependent kinase II, an increase in the phosphorylation of 5-HT 2A receptors by these enzymes during agonist-induced desensitization has yet to be shown (Gray et al., 2003) .
Phosphorylation of G
To examine the hypothesis that DOI-induced phosphorylation of G ␣11 results in the uncoupling of G protein with 5-HT 2A receptors, cells were transfected with either the phosphorylation state mimic G ␣11 S154D or wild-type G ␣11 . Fortyeight hours after transfection, the (Battaglia et al., 1984) , some receptors can exist in a high-affinity state that is not coupled to G ␣ as suggested by a revised ternary model for 5-HT 2A receptors (Egan et al., 2000; Roth et al., 1997) . Based on the revised ternary model, GTP␥S-sensitive binding would be the better index of receptor-G protein coupling. In cells transfected with either wild-type or mutant G ␣11 proteins, we found some agonist binding remaining after adding GTP␥S, suggesting that there is a population of 5-HT 2A receptor proteins in the membrane that is able to bind agonist but is not G protein-coupled, consistent with the revised ternary model for 5-HT 2A receptors (Egan et al., 2000; Roth et al., 1997) .
Phosphorylation of G ␣11 protein could hinder the coupling to 5-HT 2A receptors by either directly interrupting of the interaction of G ␣11 protein with 5-HT 2A receptors or by directly interrupting the interaction of G ␤␥ with G ␣11 protein and thereby preventing the formation of the heterotrimeric G protein complex, which binds to 5-HT 2A receptors. Phosphorylation of tyrosine residues in G ␣q/11 proteins disrupts the interaction of G ␣q/11 proteins with M 1 muscarinic receptors (Umemori et al., 1997) . Protein kinase C-mediated phosphorylation of G ␣z prevents association with G ␤␥ and conversely association of G␣ z with G␤␥ prevents phosphorylation in vitro (Fields and Casey, 1995) . However, G ␣z is primarily phosphorylated at Ser27 and is also phosphorylated at Ser16. Likewise, protein kinase C-mediated phosphorylation of G ␣12 in cells and in vitro is prevented by its interaction with G ␤␥ (Kozasa and Gilman, 1996) . However, G ␣12 is also phosphorylated in the amino terminus of the protein, possibly within the first 50 amino acids based on digestion experiments. Previous studies have also shown that the amino terminus of G ␣q is important for binding to G ␤␥ , especially isoleucine 25 (Evanko et al., 2005) . These results make decreased binding of G ␤␥ to Ser154-phosphorylated G ␣q/11 a less likely possibility. Previous studies have also found that phosphorylation of G ␣ proteins can reduce binding to other proteins. For example, phosphorylation of G ␣i2 inhibits interaction with the effector enzyme (Strassheim and Malbon, 1994) , and phosphorylation of G ␣z inhibits interaction with regulator of G protein signaling (RGS) proteins (Glick et al., 1998) .
In vivo, sustained treatment with DOI decreases the maximal response (E max ) of 5-HT-stimulated PLC activity and increases the phosphorylation of G ␣q/11 proteins. Maximal 5-HT-stimulated PLC activity was reduced in frontal cortex by 32% after 4 days and 40% after 7 days of DOI treatment. In the frontal cortex, phosphorylated G ␣q/11 proteins increase gradually and are 31% above control levels after 4 days and 51% above control levels after 7 days of DOI treatment. The time course and magnitude of the increase in phosphorylation of G ␣q/11 proteins correlates with the time course and magnitude of the desensitization 5-HT 2A receptor-mediated PLC activity; although at 4 days of DOI, the increase in phosphorylation was not statistically significant. The lack of a statistically significant increase in phosphorylation of G ␣q/11 proteins after 4 days of DOI is probably due to experimental variability in the immunoprecipitation and Western blot analysis. These correlational results, together with the cell culture data, suggest that the increase in phosphorylated G ␣11 protein contributes to desensitization of 5-HT 2A receptors in the frontal cortex. Although for the rat brain experiments, we cannot distinguish between phosphorylation of G ␣q and G ␣11 protein because the immunoprecipitation assay can only be performed with an antibody that cannot distinguish between the proteins, the cell culture data suggest that phosphorylation of only G ␣11 is likely contributing to the desensitization response in frontal cortex. Sustained DOI treatment for 4 and 7 days induces desensitization of PLC activity stimulated by an E max concentration of 5-HT. This treatment does not, however, induce a desensitization of GTP␥S-mediated PLC activity in the frontal cortex. These differential effects suggest that the desensitization of 5-HT 2A receptor signaling is due to a disruption between the receptor and the G protein and not between the G protein and the effector.
This regulation of phosphorylated G ␣q/11 proteins is treatment-specific because it occurs with agonist-induced desensitization of 5-HT 2A receptors but not with chronic fluoxetine treatment. Chronic stimulation of 5-HT 2A receptors as found with fluoxetine treatment, resulted in an increase in 5-HTstimulated PLC activity in the frontal cortex (Damjanoska et al., 2003) , rather than a decrease in 5-HT-stimulated PLC activity as seen with sustained DOI treatment. The increase in PLC activity induced by chronic fluoxetine was not accompanied by a change in phosphorylation of G ␣q/11 proteins. Chronic activation of other 5-HT receptors by fluoxetine treatment, notably 5-HT 1A receptors, probably has an impact on the regulation of 5-HT 2A receptor signaling (Darmani et al., 1990; Krebs-Thomson and Geyer, 1998; Zhang et al., 2001) and possibly the phosphorylation of G ␣q/11 protein. It is clinically relevant to determine whether stimulation of other serotonin receptors, such as 5-HT 1A receptors, inhibits phosphorylation of G ␣11 protein in future studies. Alternately, desensitization of 5-HT 1A receptors, as found with chronic fluoxetine treatment, could prevent G ␣11 protein phosphorylation.
In conclusion, the present data support the hypothesis that phosphorylation of G ␣11 proteins induced by DOI treatment causes uncoupling of 5-HT 2A receptors with G ␣11 protein in A1A1v cells and thereby contributes to desensitization of 5-HT 2A receptor signaling. The in vivo data demonstrate that increased phosphorylation of G ␣q/11 proteins correlates with desensitization of 5-HT 2A receptor signaling in rat frontal cortex, suggesting that similar mechanisms are involved in desensitization in vivo as in A1A1v cells.
